The effect of polygenic risk score and childhood adversity on transdiagnostic symptom dimensions at first-episode psychosis: evidence for an affective pathway to psychosis.

Humans Female Male Multifactorial Inheritance Psychotic Disorders / genetics Adverse Childhood Experiences / psychology Adult Bipolar Disorder / genetics Depressive Disorder, Major / genetics Case-Control Studies Schizophrenia / genetics Genetic Predisposition to Disease Young Adult Gene-Environment Interaction Adolescent Risk Factors Middle Aged Genetic Risk Score

Journal

Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664

Informations de publication

Date de publication:
26 Oct 2024
Historique:
received: 07 03 2024
accepted: 02 10 2024
revised: 20 09 2024
medline: 27 10 2024
pubmed: 27 10 2024
entrez: 27 10 2024
Statut: epublish

Résumé

Childhood adversity is associated with various clinical dimensions in psychosis; however, how genetic vulnerability shapes the adversity-associated psychopathological signature is yet to be studied. We studied data of 583 First Episode Psychosis (FEP) cases from the EU-GEI FEP case-control study, including Polygenic risk scores for major depressive disorder (MDD-PRS), bipolar disorder (BD-PRS) and schizophrenia (SZ-PRS); childhood adversity measured with the total score of the Childhood Trauma Questionnaire (CTQ); and positive, negative, depressive and manic psychopathological domains from a factor model of transdiagnostic dimensions. Genes and environment interactions were explored as a departure from a multiplicative effect of PRSs and total CTQ on each dimension. Analyses were adjusted for age, sex, 10 PCA, site of recruitment and for medication. A childhood adversity and PRS multiplicative interaction was observed between A) the CTQ and MDD-PRS on the predominance of positive (β = 0.42, 95% CI = [0.155, 0.682], p = 0.004); and depressive (β = 0.33, 95% CI = [0.071, 0.591], p = 0.013) dimensions; B) between the CTQ and BD-PRS on the positive dimension (β = 0.45, 95% CI = [0.106, 0.798], p = 0.010), and C) with the CTQ and SZ-PRS on the positive dimension (β = -0.34, 95% CI = [-0.660, -0.015], p = 0.040). Bonferroni corrected p-value of significance was set at 0.0125. In conclusion, despite being underpowered, this study suggests that genetic liability for MDD and BD may have a moderating effect on the sensibility of childhood adversity on depressive and positive psychotic dimensions. This supports the hypothesis of an affective pathway to psychosis in those exposed to childhood adversity.

Identifiants

DOI: 10.1038/s41398-024-03149-7 PMID: 39461938
pubmed: 39461938
doi: 10.1038/s41398-024-03149-7
pii: 10.1038/s41398-024-03149-7
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

454

Informations de copyright

© 2024. The Author(s).

Références

Aas M, Henry C, Andreassen OA, Bellivier F, Melle I, Etain B. The role of childhood trauma in bipolar disorders. Int J Bipolar Disord. 2016;4:2.
doi: 10.1186/s40345-015-0042-0 pubmed: 26763504 pmcid: 4712184
Varese F, Smeets F, Drukker M, Lieverse R, Lataster T, Viechtbauer W, et al. Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective- and cross-sectional cohort studies. Schizophr Bull. 2012;38:661–71.
doi: 10.1093/schbul/sbs050 pubmed: 22461484 pmcid: 3406538
Rodriguez V, Alameda L, Trotta G, Spinazzola E, Marino P, Matheson SL, et al. Environmental risk factors in bipolar disorder and psychotic depression: a systematic review and meta-analysis of prospective studies. Schizophr Bull. 2021.
Alameda L, Ashok A, Avery S, Bani-Fatemi A, Berkhout S, Best M, et al. The 2019 Schizophrenia International Research Society Conference, 10-14 April, Orlando, Florida: A summary of topics and trends. Psychiatry Res. 2019: 112672.
Alameda L, Christy A, Rodriguez V, Salazar de Pablo G, Thrush M, Shen Y, et al. Association between specific childhood adversities and symptom dimensions in people with psychosis: systematic review and meta-analysis. Schizophr Bull. 2021.
Christy A, Cavero D, Navajeeva S, Murray-O’Shea R, Rodriguez V, Aas M, et al. Association between childhood adversity and functional outcomes in people with psychosis: a meta-analysis. Schizophr Bull. 2023;49:285–96.
doi: 10.1093/schbul/sbac105 pubmed: 36107860
Alameda L, Rodriguez V, Carr E, Aas M, Trotta G, Marino P, et al. A systematic review on mediators between adversity and psychosis: potential targets for treatment. Psychological Med. 2020;50:1966–76.
doi: 10.1017/S0033291720002421
Sideli L, Murray RM, Schimmenti A, Corso M, La Barbera D, Trotta A, et al. Childhood adversity and psychosis: a systematic review of bio-psycho-social mediators and moderators. Psychol Med. 2020;50:1761–82.
doi: 10.1017/S0033291720002172 pubmed: 32624020
Pardiñas AF, Holmans P, Pocklington AJ, Escott-Price V, Ripke S, Carrera N, et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat Genet. 2018;50:381–9.
doi: 10.1038/s41588-018-0059-2 pubmed: 29483656 pmcid: 5918692
Stahl EA, Breen G, Forstner AJ, McQuillin A, Ripke S, Trubetskoy V, et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. Nat Genet. 2019;51:793–803.
doi: 10.1038/s41588-019-0397-8 pubmed: 31043756 pmcid: 6956732
Howard DM, Adams MJ, Clarke TK, Hafferty JD, Gibson J, Shirali M, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat Neurosci. 2019;22:343–52.
doi: 10.1038/s41593-018-0326-7 pubmed: 30718901 pmcid: 6522363
Woolway GE, Smart SE, Lynham AJ, Lloyd JL, Owen MJ, Jones IR et al. Schizophrenia polygenic risk and experiences of childhood adversity: a systematic review and meta-analysis. Schizophr Bull. 2022.
Woolway GE, Smart SE, Lynham AJ, Lloyd JL, Owen MJ, Jones IR, et al. Schizophrenia polygenic risk and experiences of childhood adversity: a systematic review and meta-analysis. Schizophr Bull. 2022;48:967–80.
doi: 10.1093/schbul/sbac049 pubmed: 35674151 pmcid: 9434424
Guloksuz S, Pries LK, Delespaul P, Kenis G, Luykx JJ, Lin BD, et al. Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study. World Psychiatry. 2019;18:173–82.
doi: 10.1002/wps.20629 pubmed: 31059627 pmcid: 6502485
Aas M, Alameda L, Di Forti M, Quattrone D, Dazzan P, Trotta A et al. Synergistic effects of childhood adversity and polygenic risk in first-episode psychosis: the EU-GEI study. Psychol Med. 2021: 1-9.
Trotta A, Iyegbe C, Di Forti M, Sham PC, Campbell DD, Cherny SS, et al. Interplay between schizophrenia polygenic risk score and childhood adversity in first-presentation psychotic disorder: a pilot study. PLoS ONE. 2016;11:e0163319.
doi: 10.1371/journal.pone.0163319 pubmed: 27648571 pmcid: 5029892
Sideli L, Aas M, Quattrone D, La Barbera D, La Cascia C, Ferraro L, et al. The relationship between genetic liability, childhood maltreatment, and IQ: findings from the EU-GEI multicentric case-control study. Soc Psychiatry Psychiatr Epidemiol. 2023;58:1573–80.
doi: 10.1007/s00127-023-02513-0 pubmed: 37335320 pmcid: 10460355
Rodriguez V, Alameda L, Quattrone D, Tripoli G, Gayer-Anderson C, Spinazzola E et al. Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study. Psychol. Med. 2022: 1-10.
Gayer-Anderson C, Jongsma HE, Di Forti M, Quattrone D, Velthorst E, de Haan L, et al. The EUropean Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI): incidence and first-episode case-control programme. Soc Psychiatry Psychiatr Epidemiol. 2020;55:645–57.
doi: 10.1007/s00127-020-01831-x pubmed: 31974809
Di Forti M, Quattrone D, Freeman TP, Tripoli G, Gayer-Anderson C, Quigley H, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6:427–36.
doi: 10.1016/S2215-0366(19)30048-3 pubmed: 30902669 pmcid: 7646282
Quattrone D, Di Forti M, Gayer-Anderson C, Ferraro L, Jongsma HE, Tripoli G et al. Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study. Psychol Med. 2018: 1-14.
McGuffin P, Farmer A, Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness: development and reliability of the OPCRIT system. Arch Gen Psychiatry. 1991;48:764–70.
doi: 10.1001/archpsyc.1991.01810320088015 pubmed: 1883262
Jongsma HE, Gayer-Anderson C, Lasalvia A, Quattrone D, Mulè A, Szöke A, et al. Treated incidence of psychotic disorders in the multinational EU-GEI study. JAMA psychiatry. 2018;75:36–46.
doi: 10.1001/jamapsychiatry.2017.3554 pubmed: 29214289
Mallett R, Leff J, Bhugra D, Pang D, Zhao JH. Social environment, ethnicity and schizophrenia. A case-control study. Soc psychiatry Psychiatr Epidemiol. 2002;37:329–35.
doi: 10.1007/s00127-002-0557-4 pubmed: 12111025
Bernstein DP, Stein JA, Newcomb MD, Walker E, Pogge D, Ahluvalia T, et al. Development and validation of a brief screening version of the Childhood Trauma Questionnaire. Child Abus Negl. 2003;27:169–90.
doi: 10.1016/S0145-2134(02)00541-0
Bernstein DP, Fink L, Handelsman L, Foote J, Lovejoy M, Wenzel K, et al. Initial reliability and validity of a new retrospective measure of child abuse and neglect. Am J Psychiatry. 1994.
Sætren SS, Bjørnestad JR, Ottesen AA, Fisher HL, Olsen DAS, Hølland K, et al. Unraveling the concept of childhood adversity in psychosis research: a systematic review. Schizophr Bull. 2024.
Association AAP. Diagnostic and statistical manual of mental disorders (DSM-IV). Washington, DC: American Psychiatric Association; 1994.
Quattrone D, Reininghaus U, Richards AL, Tripoli G, Ferraro L, Quattrone A, et al. The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study. Transl Psychiatry. 2021;11:423.
doi: 10.1038/s41398-021-01526-0 pubmed: 34376640 pmcid: 8355107
Ferraro L, La Cascia C, La Barbera D, Sanchez-Gutierrez T, Tripoli G, Seminerio F, et al. The relationship of symptom dimensions with premorbid adjustment and cognitive characteristics at first episode psychosis: Findings from the EU-GEI study. Schizophr Res. 2021;236:69–79.
doi: 10.1016/j.schres.2021.08.008 pubmed: 34403965 pmcid: 8473991
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–76.
doi: 10.1093/schbul/13.2.261 pubmed: 3616518
Rodriguez V, Alameda L, Quattrone D, Tripoli G, Gayer-Anderson C, Spinazzola E, et al. Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study. Psychol Med. 2023;53:3396–405.
doi: 10.1017/S0033291721005456 pubmed: 35076361
Choi SW, O’Reilly PF. PRSice-2: Polygenic Risk Score software for biobank-scale data. Gigascience 2019; 8.
Trubetskoy V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature. 2022;604:502–8.
doi: 10.1038/s41586-022-04434-5 pubmed: 35396580 pmcid: 9392466
Mullins N, Forstner AJ, O’Connell KS, Coombes B, Coleman JRI, Qiao Z, et al. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nat Genet. 2021;53:817–29.
doi: 10.1038/s41588-021-00857-4 pubmed: 34002096 pmcid: 8192451
Curtis D. Polygenic risk score for schizophrenia is more strongly associated with ancestry than with schizophrenia. Psychiatr Genet. 2018;28:85–89.
doi: 10.1097/YPG.0000000000000206 pubmed: 30160659
Vassos E, Di Forti M, Coleman J, Iyegbe C, Prata D, Euesden J, et al. An examination of polygenic score risk prediction in individuals with first-episode psychosis. Biol Psychiatry. 2017;81:470–7.
doi: 10.1016/j.biopsych.2016.06.028 pubmed: 27765268
Keller MC. Gene × environment interaction studies have not properly controlled for potential confounders: the problem and the (simple) solution. Biol Psychiatry. 2014;75:18–24.
doi: 10.1016/j.biopsych.2013.09.006 pubmed: 24135711
Trotta A, Di Forti M, Iyegbe C, Green P, Dazzan P, Mondelli V, et al. Familial risk and childhood adversity interplay in the onset of psychosis. BJPsych Open. 2015;1:6–13.
doi: 10.1192/bjpo.bp.115.000158 pubmed: 27703716 pmcid: 4995579
Howes OD, Murray RM. Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet. 2014;383:1677–87.
doi: 10.1016/S0140-6736(13)62036-X pubmed: 24315522
van Os J, Pries L-K, Ten Have M, de Graaf R, van Dorsselaer S, Delespaul P, et al. Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway. Psychological Med. 2022;52:1910–22.
doi: 10.1017/S0033291720003748
Bebbington P. Unravelling psychosis: psychosocial epidemiology, mechanism, and meaning. Shanghai Arch Psychiatry. 2015;27:70–81.
pubmed: 26120255 pmcid: 4466846
Upthegrove R, Ross K, Brunet K, McCollum R, Jones L. Depression in first episode psychosis: the role of subordination and shame. Psychiatry Res. 2014;217:177–84.
doi: 10.1016/j.psychres.2014.03.023 pubmed: 24726817
Alameda L, Golay P, Baumann PS, Progin P, Mebdouhi N, Elowe J, et al. Mild depressive symptoms mediate the impact of childhood trauma on long-term functional outcome in early psychosis patients. Schizophr Bull. 2017;43:1027–35.
doi: 10.1093/schbul/sbw163 pubmed: 27884931
Fares-Otero NE, Alameda L, Pfaltz MC, Martinez-Aran A, Schäfer I, Vieta E. Examining associations, moderators and mediators between childhood maltreatment, social functioning, and social cognition in psychotic disorders: a systematic review and meta-analysis. Psychol Med. 2023: 1-24.
Ramain J, Conus P, Golay P. Interactions between mood and paranoid symptoms affect suicidality in first-episode affective psychoses. Schizophr Res. 2023;254:62–67.
doi: 10.1016/j.schres.2022.12.035 pubmed: 36801515
Lewis CM, Vassos E. Polygenic risk scores: from research tools to clinical instruments. Genome Med. 2020;12:44.
doi: 10.1186/s13073-020-00742-5 pubmed: 32423490 pmcid: 7236300
Baldwin JR, Reuben A, Newbury JB, Danese A. Agreement between prospective and retrospective measures of childhood maltreatment: a systematic review and meta-analysis. JAMA Psychiatry. 2019;76:584–93.
doi: 10.1001/jamapsychiatry.2019.0097 pubmed: 30892562 pmcid: 6551848
Reuben A, Moffitt TE, Caspi A, Belsky DW, Harrington H, Schroeder F, et al. Lest we forget: comparing retrospective and prospective assessments of adverse childhood experiences in the prediction of adult health. J Child Psychol Psychiatry. 2016;57:1103–12.
doi: 10.1111/jcpp.12621 pubmed: 27647050 pmcid: 5234278

Auteurs

Luis Alameda (L)

Service of General Psychiatry, Treatment and Early Intervention in Psychosis Program, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College of London, London, UK.
Instituto de Investigación Sanitaria de Sevilla, IbiS, Hospital Universitario Virgen del Rocío, Department of Psychiatry, Universidad de Sevilla, Sevilla, Spain.
ORCID: 0000-0002-8621-2885

Victoria Rodriguez (V)

Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College of London, London, UK.

Marta Di Forti (M)

Social, Genetics and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
ORCID: 0000-0002-3218-6925

Edoardo Spinazzola (E)

Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College of London, London, UK.

Giulia Trotta (G)

Social, Genetics and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Celso Arango (C)

Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, CIBERSAM, Madrid, Spain.
ORCID: 0000-0003-3382-4754

Manuel Arrojo (M)

Department of Psychiatry, Psychiatric Genetic Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago, Spain.

Miguel Bernardo (M)

Barcelona Clinic Schizophrenia Unit, Hospital Clinic, Departament de Medicina, Institut de Neurociències (UBNeuro), Universitat de Barcelona (UB), Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), CIBERSAM, ISCIII, Barcelona, Spain.
ORCID: 0000-0001-8748-6717

Julio Bobes (J)

Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain.
Department of Medicine, Psychiatry Area, School of Medicine, Universidad de Oviedo, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Oviedo, Spain.
ORCID: 0000-0003-2187-4033

Lieuwe de Haan (L)

Department of Psychiatry, Early Psychosis Section, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Cristina Marta Del-Ben (CM)

Neuroscience and Behaviour Department, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
ORCID: 0000-0003-0145-9975

Charlotte Gayer-Anderson (C)

ESRC Centre for Society and Mental Health, King's College London, London, UK.

Lucia Sideli (L)

Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College of London, London, UK.
Department of Human Science, LUMSA University, Rome, Italy.
Section of Psychiatry, Department of Biomedicine, Neuroscience and advanced Diagnostic (BiND), University of Palermo, Palermo, Italy.

Peter B Jones (PB)

Department of Psychiatry, University of Cambridge, Cambridge, UK.
CAMEO Early Intervention Service, Cambridgeshire & Peterborough NHS Foundation Trust, Cambridge, UK.
Psylife Group, Division of Psychiatry, University College London, London, UK.
ORCID: 0000-0002-0387-880X

James B Kirkbride (JB)

Psylife Group, Division of Psychiatry, University College London, London, UK.
ORCID: 0000-0003-3401-0824

Caterina La Cascia (C)

Section of Psychiatry, Department of Biomedicine, Neuroscience and advanced Diagnostic (BiND), University of Palermo, Palermo, Italy.

Giada Tripoli (G)

Section of Psychiatry, Department of Biomedicine, Neuroscience and advanced Diagnostic (BiND), University of Palermo, Palermo, Italy.

Laura Ferraro (L)

Section of Psychiatry, Department of Biomedicine, Neuroscience and advanced Diagnostic (BiND), University of Palermo, Palermo, Italy.

Daniele La Barbera (D)

Section of Psychiatry, Department of Biomedicine, Neuroscience and advanced Diagnostic (BiND), University of Palermo, Palermo, Italy.

Antonio Lasalvia (A)

Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy.

Sarah Tosato (S)

Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy.
ORCID: 0000-0002-9665-7538

Pierre-Michel Llorca (PM)

Université Clermont Auvergne, Clermont-Ferrand, France.
ORCID: 0000-0001-7438-8990

Paulo Rossi Menezes (PR)

Department of Preventive Medicine, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
ORCID: 0000-0001-6330-3314

Jim van Os (J)

Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College of London, London, UK.
Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, Maastricht, The Netherlands.
Department Psychiatry, Brain Centre Rudolf Magnus, Utrecht University Medical Centre, Utrecht, The Netherlands.
ORCID: 0000-0002-7245-1586

Bart P Rutten (BP)

Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, Maastricht, The Netherlands.
ORCID: 0000-0002-9834-6346

Jose Luis Santos (JL)

Department of Psychiatry, Servicio de Psiquiatría Hospital "Virgen de la Luz", C/Hermandad de Donantes de Sangre, 16002, Cuenca, Spain.

Julio Sanjuán (J)

Department of Psychiatry, School of Medicine, Universidad de Valencia, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), C/Avda. Blasco Ibáñez 15, 46010, Valencia, Spain.

Jean-Paul Selten (JP)

Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, Maastricht, The Netherlands.
Rivierduinen Institute for Mental Health Care, Leiden, The Netherlands.

Andrei Szöke (A)

University of Paris Est Creteil, INSERM, IMRB, AP-HP, Hôpitaux Universitaires, H. Mondor, DMU IMPACT, Creteil, France.

Ilaria Tarricone (I)

Bologna Transcultural Psychosomatic Team (BoTPT), Department of Medical and Surgical Science, Alma Mater Studiorum Università di Bologna, Bologna, Italy.
ORCID: 0000-0002-5786-2520

Andrea Tortelli (A)

Institut Mondor de recherché biomedicale, Creteil, France.

Eva Velthorst (E)

Department of Research, Community Mental Health Service, GGZ Noord-Holland-Noord, Heerhugowaard, The Netherlands.
ORCID: 0000-0002-9240-2909

Hannah E Jongsma (HE)

Centre for Transcultural Psychiatry 'Veldzicht', Balkbrug, The Netherlands.

Evangelos Vassos (E)

Social, Genetics and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
ORCID: 0000-0001-6363-0438

Diego Quattrone (D)

Social, Genetics and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Robin M Murray (RM)

Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College of London, London, UK.
ORCID: 0000-0003-0829-0519

Monica Aas (M)

Social, Genetics and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. monica.aas@kcl.ac.uk.
ORCID: 0000-0002-2338-5826

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The effect of polygenic risk score and...
questionsmedicales.fr › Phénomènes génétiques › Modes de transmission héréditaire › Hérédité multifactorielle › The effect of polygenic risk score and...
questionsmedicales.fr › Troubles mentaux › Schizophrénie et troubles avec traits psychotiques › Troubles psychotiques › The effect of polygenic risk score and...
questionsmedicales.fr › Sciences sociales › Sociologie › Facteurs sociologiques › Expériences défavorables de l'enfance › The effect of polygenic risk score and...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › The effect of polygenic risk score and...
questionsmedicales.fr › Troubles mentaux › Troubles de l'humeur › Troubles bipolaires et apparentés › Trouble bipolaire › The effect of polygenic risk score and...
questionsmedicales.fr › Troubles mentaux › Troubles de l'humeur › Trouble dépressif › Trouble dépressif majeur › The effect of polygenic risk score and...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études cas-témoins › The effect of polygenic risk score and...
questionsmedicales.fr › Troubles mentaux › Schizophrénie et troubles avec traits psychotiques › Schizophrénie › The effect of polygenic risk score and...
questionsmedicales.fr › Phénomènes génétiques › Génotype › Prédisposition génétique à une maladie › The effect of polygenic risk score and...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Jeune adulte › The effect of polygenic risk score and...
questionsmedicales.fr › Phénomènes génétiques › Phénotype › Interaction entre gènes et environnement › The effect of polygenic risk score and...
questionsmedicales.fr › Personnes › Tranches d'âge › Adolescent › The effect of polygenic risk score and...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Facteurs de risque › The effect of polygenic risk score and...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › The effect of polygenic risk score and...